Restorative Parkinson Unit
16 – 30 of 111
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training
(
- Contribution to journal › Article
-
Mark
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum : Revelations from the MANAGE-PD validation cohort
(
- Contribution to journal › Article
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
-
Mark
The Relationship between PDQ-8 and Costs in Parkinson's Disease—A Swedish Register-Based Study
(
- Contribution to journal › Article
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease : Real-World Evidence From G7 Countries
(
- Contribution to journal › Article
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
(
- Contribution to journal › Article
-
Mark
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article